Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP

Figures & data

Table 1. Summary of the selected patients who switched to rVIII-SingleChain.

Country	Patient characteristics	Previous treatment	rVIII‑SingleChain prophylaxis regimen
Germany	18-year-old	pdFVIII (2000 IU, 3×/week); this provided a FVIII trough level of 0.5–1% after 72 h	2000 IU, 3×/week; this achieved a FVIII trough level of 3% after 72 h and a half-life of 15 h
Germany	Pediatric patient	pdFVIII (1000 IU 3×/week)	1000 IU, 3×/week
France	15-year-old	rFVIII (1500 IU, 3×/week); this provided a FVIII trough level of 3.1% after 48 h and a half-life of 11.1 h	1500 IU, 3×/week; this provided a FVIII trough level of 10.2% after 48 h and a half-life of 17.2 h. After 5 months, the regimen was changed to 2000 IU, 2×/week
Germany	60-year-old	rFVIII (2000 IU every 2 days, 100 IU/kg/week); this provided a 3-day FVIII trough level of 2.4%	3000 IU, 2×/week, 81 IU/kg; this provided a 3-day FVIII trough level of 6.7%
Italy	2-year-old	None [previously untreated patient]	35 IU/kg, 2×/week

FVIII: factor VIII; pdFVIII: plasma-derived factor VIII; rFVIII: recombinant factor VIII.

Table 2. Summary of the selected patients who switched to rIX-FP.

Country	Patient characteristics	Previous treatment	rIX-FP prophylaxis regimen
Germany	21-year-old	rFIX (2000 IU 3×/week); this provided a FIX trough level of 2% after 72 h	4000 IU, every 10 days; this provided a FIX trough level of 10% after 10 days and a half-life of 140 h
Italy	6-year-old	Standard-acting FIX (40 IU/kg 2×/week)	50 IU/kg, 1×/week
Italy	71-year-old	Episodic treatment with pdFIX	Post-operative regimen: 50 IU/kg, every 10 days. Prophylaxis regimen: 40 IU/kg, 1×/week; this provided a FIX trough level of 10%
Israel	16-year-old	pdFIX (40 IU/kg, 2×/week)	75 IU/kg, every 10 days
Switzerland	43-year-old	Episodic treatment with pdFIX	50 IU/kg, every 14 days

FIX: factor IX; pdFIX: plasma-derived factor IX; rFIX: recombinant factor IX.